We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study
Effectiveness of one-year treatment with liraglutide and semaglutide on weight regain after weight-loss surgery
AI simplified
Abstract
Patients experienced a median weight loss of 10.5 kg after 12 months of GLP1-RA treatment for weight regain following .
- Forty patients, predominantly female (80%), were analyzed for weight regain treatment.
- , liraglutide and semaglutide, were initiated after a median of 74.5 months post-surgery following a weight regain of 14.7%.
- The treatment resulted in a reduction of BMI by 3.7 kg/m and a percentage of excess body weight loss of 41.7%, equating to 99.3% of the regained weight.
- A significant difference in BMI reduction was observed, with liraglutide showing a lower reduction compared to semaglutide (3.1 kg/m vs. 4.7 kg/m).
- Adverse events occurred in 32.5% of patients, but all were mild and transient.
AI simplified
Key numbers
10.5 kg
Weight Loss Achieved
Median total body weight loss after 12 months of treatment.
99.3%
Percentage of Regained Weight Lost
Percentage of previously regained weight lost after treatment.
4.7 kg/m
Reduction with
Median reduction after 12 months of treatment with .